Pedro Hashizume
@HashizumePedro
Followers
211
Following
262
Statuses
248
Medical Oncologist at ICESP/USP and Oncologia D'Or
Sao Paulo, Brazil
Joined September 2019
Check out our paper @LancetRH_Americ Nice multicenter collaborative effort! Cholangiocarcinoma in Latin America: a multicentre observational study alerts on ethnic disparities in tumour presentation and outcomes - The Lancet Regional Health – Americas
0
2
5
Result of great teamwork from our friends at @Icesp_ ! Nice job !!
Excited to share our publication in JCO Global Oncology! We analyzed the patterns of unplanned hospitalization among cancer patients in the Brazilian health system. Recognizing these patterns is key to improving cancer care in our country.
0
0
2
Tremendous achievement of @_hanielaraujo and cols in this publication in Cancer Discovery! Congrats my friend!!!
A mucinous transcriptional program supports long-term tumor cell persistence to RAS inhibitors and mucinous histological features may predict poor resposme to KRAS G12C inhibitors. These important findings provide new insights for drug development targeting KRAS-mutant NSCLC.
1
0
14
@dr_yakupergun @OncoAlert @Annals_Oncology Dr, despite numerical difference and myself belief in TNT benefit, what about statistical plan modification from original? I mean, analysis from the original plan, turns the results negative.
0
0
2
The standards for approvals should be higher Surrogate endpoints must be well validated to become useful Unfortunately, physician's choice isnt the best choice. Then regulatory agencies may balance that.
Out in @TheLancetOncol in OA The OS benefits of cancer drugs approved by surrogate endpoints ☑️38 indications with OS data after approval ❎Significant OS benefit in only 32% of the indications ❎Late availability of (>3 years) non-significant OS results The value of surrogate endpoints in approvals ❓❓ A double-edged sword ⚔️ #OncoAlertAF #CSO @OncoAlert
@VPrasadMDMPH @oncology_bg @darioT_ @cspramesh
@ASCO @myESMO @ESOncology @LSEnews
1
0
9
@SuyogCancer @rushabh1388 @myESMO Dr, do you think Pembro for 2 years should be broadly used in LACC? A subgroup would be cured with just CRT, and benefit is still PFS only (besides subsequent treatemens discussion...)
1
0
2
0
0
5
RT @felippelazar: Our work in global representativeness, pharm. funding and cost-effectiveness research have recently been published at The…
0
7
0